Sean Robert O'Malley

US Patent:

7145025, Dec 5, 2006

Filed:

Jul 29, 2003

Appl. No.:

10/629538

Inventors:

Samuel Fournier Lockwood - Lago Vista TX, US
Sean O'Malley - Honolulu HI, US
David G. Watumull - Honolulu HI, US
Laura M. Hix - Honolulu HI, US
Henry Jackson - Honolulu HI, US
Geoff Nadolski - Kaaawa HI, US

Assignee:

Hawaii Biotech, Inc. - Aiea HI

International Classification:

A61K 31/341

US Classification:

549473

Abstract:

A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structural analog, either alone or in combination with another carotenoid analog, or co-antioxidant formulation. The analog or analog combination is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of ischemia-reperfusion injury, liver disease, cancer, cardiac arrhythmia and/or sudden cardiac death, and/or any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In one embodiment, a water-soluble and/or water-dispersible astaxanthin analog is particularly effective. This invention further includes pharmaceutical compositions comprising structural carotenoid analogs either alone or in combination.

US Patent:

7592449, Sep 22, 2009

Filed:

Feb 17, 2006

Appl. No.:

11/357897

Inventors:

Samuel Fournier Lockwood - Lago Vista TX, US
Sean O'Malley - Honolulu HI, US
David G. Watumull - Honolulu HI, US
Laura M. Hix - Honolulu HI, US
Henry Jackson - Honolulu HI, US
Geoff Nadolski - Kaaawa HI, US

Assignee:

Cardax Pharmaceuticals, Inc. - Aiea HI

International Classification:

C07D 233/12
C07D 265/30
C07D 473/00

US Classification:

544106, 544264, 5483511, 549315, 549415

Abstract:

A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structural analog, either alone or in combination with another carotenoid analog, or co-antioxidant formulation. The analog or analog combination is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of ischemia-reperfusion injury. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of liver disease. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cancer.

US Patent:

7691901, Apr 6, 2010

Filed:

Apr 14, 2005

Appl. No.:

11/106378

Inventors:

Samuel Fournier Lockwood - Lago Vista TX, US
Sean O'Malley - Honolulu HI, US
Henry Jackson - Honolulu HI, US
Geoff Nadolski - Kaneohe HI, US

Assignee:

Cardax Pharmaceuticals Inc. - Aiea HI

International Classification:

A61K 31/341
A61K 31/351

US Classification:

514460, 514473

Abstract:

A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate the occurrence of diseases in subjects. In some embodiments, analogs or derivatives of carotenoids may be water-soluble and/or water dispersible. Maladies that may be treated with analogs or derivatives of carotenoids embodied herein may include diseases that provoke or trigger an inflammatory response. In an embodiment, asthma may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of eicosanoids. In an embodiment, atherosclerosis may be treated with analogs or derivatives of carotenoids embodied herein.

US Patent:

20060058269, Mar 16, 2006

Filed:

Aug 29, 2005

Appl. No.:

11/214478

Inventors:

Samuel Lockwood - Lago Vista TX, US
Sean O'Malley - Honolulu HI, US
Henry Jackson - Honolulu HI, US
Geoff Nadolski - Kaneohe HI, US

International Classification:

A61K 31/66
A61K 31/015

US Classification:

514124000, 514763000

Abstract:

A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate the occurrence of diseases in subjects. In some embodiments, analogs or derivatives of carotenoids may be water-soluble and/or water dispersible. Maladies that may be treated with analogs or derivatives of carotenoids embodied herein may include diseases that provoke or trigger an inflammatory response. In an embodiment, asthma may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of eicosanoids. In an embodiment, atherosclerosis may be treated with analogs or derivatives of carotenoids embodied herein. In an embodiment, administering the analogs or derivatives of carotenoids embodied herein to a subject may control or affect the bioavailability of 5-LO-catalyzed eicosanoid metabolites. In an embodiment, 5-LO-catalyzed eicosanoid metabolites that may be controlled or affected by administering analogs or derivatives of carotenoids to a subject may include proinflammatory effector molecules (e.g., leukotrienes).